Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

31. Oktober 2017 07:00 ET | Quelle: ObsEva SA

ObsEva SA to Hold Third Quarter 2017 Financial Results and Business Update Call on November 14, 2017 and Present at Credit Suisse and Jefferies Investor Conferences in November

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
10. Oktober 2017 08:00 ET | Quelle: ObsEva SA

ObsEva SA Announces $60.0 Million Private Placement with Existing and New Investors

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA - 10...
11. September 2017 07:00 ET | Quelle: ObsEva SA

ObsEva SA Announces Presentation Related to its PGF2alpha Receptor Antagonist at ACCP 2017 Annual Meeting

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Phase 1 clinical trial results in...
06. September 2017 07:00 ET | Quelle: ObsEva SA

ObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial in Assisted Reproductive Technology Ahead of Schedule

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
30. August 2017 07:00 ET | Quelle: ObsEva SA

ObsEva SA to Attend Baird Global Healthcare Conference and Rodman & Renshaw Annual Global Investment Conference in NYC

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA - 30...
15. August 2017 16:05 ET | Quelle: ObsEva SA

ObsEva Reports Second Quarter 2017 Financial Results and Provides Business Update

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - Patient Enrollment Progressing for...
07. August 2017 07:00 ET | Quelle: ObsEva SA

ObsEva SA to Hold Second Quarter 2017 Financial Results/Business Update Call on August 15, 2017 and Present at Wedbush PacGrow Healthcare Conference in NYC on August 16, 2017

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA - 07...
29. Juni 2017 07:00 ET | Quelle: ObsEva SA

ObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Phase 2 nolasiban previously reported...
07. Juni 2017 07:00 ET | Quelle: ObsEva SA

ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - OBE2109 is a GnRH receptor antagonist...
31. Mai 2017 07:00 ET | Quelle: ObsEva SA

ObsEva SA to Attend Jefferies Healthcare Conference in NYC

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA - 31...

Vorherige Seite